IDXX: Recurring diagnostics growth lifted FY26 revenue and EPS guidance

What happened

IDEXX Laboratories reported third-quarter revenue up 10%, with recurring CAG Diagnostics revenue up 11%. This prompted the company to raise its revenue and earnings-per-share guidance for the fiscal year. Sector visits remained pressured, while practice revenue was positive.

Confirmed

Global impact / market context

Recurring diagnostics revenue is repeat business from veterinary clinics, so growth there suggests steadier cash flow than one-time equipment sales. Higher profit guidance signals management expects stronger earnings, which can support the stock price and justify continued spending on growth.

Analyst inference

Weaker sector visits mean fewer pets brought to clinics, a headwind for the industry. IDEXX offset this with recurring diagnostic sales and positive practice revenue, showing its consumables and testing business can grow even when visit volumes are soft.

Analyst inference

What to watch

1. The company raised its full-year revenue and earnings-per-share guidance after third-quarter revenue rose 10% and recurring CAG Diagnostics revenue grew 11%. Confirmed
2. Watch whether recurring diagnostics revenue keeps growing faster than sector visits, since that gap shows clinics are testing more per patient and offsets lower visit volumes. Analyst inference
3. Monitor practice revenue trends and sector visit pressure next quarter, because a rebound in visits would add growth on top of recurring diagnostic sales and support the raised guidance. Proposed

Evidence

• Original source link unavailable